期刊
DIABETES
卷 51, 期 3, 页码 797-802出版社
AMER DIABETES ASSOC
DOI: 10.2337/diabetes.51.3.797
关键词
-
资金
- NCRR NIH HHS [M01 RR000125, M01-RR-00125] Funding Source: Medline
- NIDDK NIH HHS [R01-DK-49230, K23 DK002734, P30 DK045735, P30-DK-45735, R01 DK049230, K23 DK002734-03] Funding Source: Medline
- PHS HHS [K-23] Funding Source: Medline
- NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000125] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049230, K23DK002734, P30DK045735] Funding Source: NIH RePORTER
We examined the effect of three months of rosiglitazone treatment (4 mg b.i.d.) on whole-body insulin sensitivity and in vivo peripheral adipocyte insulin sensitivity as assessed by glycerol release in microdialysis from subcutaneous fat during a two-step (20 and 120 MU. m(-2). min(-1)) hyperinsulinemic-euglycemic clamp in nine type 2 diabetic subjects. In addition, the effects of rosiglitazone on liver and muscle triglyceride content were assessed by H-1-nuclear magnetic resonance spectroscopy. Rosiglitazone treatment resulted in a 68% (P < 0.002) and a 20% (P < 0.016) improvement in insulin-stimulated glucose metabolism during the low- and highdosage-insulin clamps, respectively, which was associated with similar to40% reductions in plasma fatty acid concentration (P < 0.05) and hepatic triglyceride content (P < 0.05). These changes were associated with a 39% increase in extramyocellular lipid content (P < 0.05) and a 52% increase in the sensitivity of peripheral adipocytes to the inhibitory effects of insulin on lipolysis (P = 0.04). In conclusion, these results support the hypothesis that thiazolidinediones enhance insulin sensitivity in patients with type 2 diabetes by promoting increased insulin sensitivity in peripheral adipocytes, which results in lower plasma fatty acid concentrations and a redistribution of intracellular lipid from insulin responsive organs into peripheral adipocytes. Diabetes 51: 797-802,2002
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据